Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

BACKGROUND: There is little evidence of the effectiveness of switching from the endothelin receptor antagonists (ERAs) bosentan and ambrisentan to a novel ERA, macitentan, in patients with pulmonary arterial hypertension (PAH). Therefore, a systematic review and meta-analysis was performed to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Yang, Zu-Yuan, Wang, Shang, Yuan, Ping, Zhao, Qin-Hua, Gong, Su-Gang, Qiu, Hong-Ling, Luo, Ci-Jun, Li, Hui-Ting, Zhang, Rui, Wu, Wen-Hui, Liu, Jin-Ming, Wang, Lan, Liu, Shan-Shan, Jiang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767980/
https://www.ncbi.nlm.nih.gov/pubmed/36568539
http://dx.doi.org/10.3389/fcvm.2022.977110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767980/
https://www.ncbi.nlm.nih.gov/pubmed/36568539
http://dx.doi.org/10.3389/fcvm.2022.977110

Ejemplares similares